05/17/22 4:05 PMNasdaq : CNTB low floatConnect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual ConferenceConnect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases throughRHEA-AIneutral
05/11/22 8:00 PMNasdaq : CNTB managementclinical triallow floatCANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and OperationsCANbridge Pharmaceuticals, Inc., a China- based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that it has appointed Pauline Li, MD, to the position of Senior Vice President of Clinical Development and Operations,...RHEA-AIvery positive
05/03/22 4:05 PMNasdaq : CNTB clinical triallow floatConnect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative ColitisPrimary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement , but did not achieve statistical significance Clinical Remission on adapted Mayo Score and other secondary endpoints achieved statisticalRHEA-AIneutral
03/31/22 4:05 PMNasdaq : CNTB earningslow floatConnect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected to Be Reported in H1 2022 - - C a sh B a l an c e o f RMB 1,706.9 million (U S D 267.7 milli o n) aRHEA-AInegative
03/01/22 8:00 AMNasdaq : CNTB managementlow floatConnect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical OfficerConnect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma," “Connect,” or theRHEA-AIvery positive
02/09/22 7:00 AMNasdaq : CNTB conferenceslow floatConnect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare ConferenceConnect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through theRHEA-AIneutral
01/24/22 7:00 AMNasdaq : CNTB clinical triallow floatConnect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baselineRHEA-AIneutral
01/05/22 7:00 AMNasdaq : CNTB clinical triallow floatConnect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo— —Additional analyses demonstrate a potentially competitive therapeutic profile for CBP-201 300mgRHEA-AIneutral
01/04/22 4:05 PMNasdaq : CNTB conferencesclinical triallow floatConnect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through theRHEA-AIneutral
01/03/22 6:00 AMNasdaq : CTKB, CNTB, EXAS Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated TherapeuticsThe funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenvironment activated therapeutic programs including bispecific...RHEA-AIpositive